Sonoma Pharmaceuticals, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

5. Inventories

5. Inventories

12 Months Ended

Mar. 31, 2014

Inventories consist of the following:

	March 31,
	2014			2013
Raw materials	$	790,000		$	835,000
Finished goods		345,000			327,000
		1,135,000			1,162,000
Less: inventory allowances		(47,000	)		(170,000	)
	$	1,088,000		$	992,000

Reserve for obsolete inventories activities are as follows:

Year Ended March 31	Balance at Beginning of Year		Additions Charged to Cost of Product Revenues		Deductions Write-Offs			Balance at End of Year
2013	$	105,000	$	85,000	$	(20,000	)	$	170,000
2014	$	170,000	$	6,000	$	(129,000	)	$	47,000

- Definition

The entire disclosure for inventory. This may include, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the major classes of inventory, and the nature of the cost elements included in inventory. If inventory is stated above cost, accrued net losses on firm purchase commitments for inventory and losses resulting from valuing inventory at the lower-of-cost-or-market may also be included. For LIFO inventory, may disclose the amount and basis for determining the excess of replacement or current cost over stated LIFO value and the effects of a LIFO quantities liquidation that impacts net income.

+ References + Details